Assessment of clinical inertia in people with diabetes within primary care
| Autor: | Ashley H. Meredith, Todd A Walroth, Emily M. Buatois, James R. Krenz, Jessica Triboletti, McKenzie Shenk, Jasmine D. Gonzalvo, Lauren Pence |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Treatment intensification education Pharmacist Primary care Pharmacists 03 medical and health sciences Interquartile range Diabetes management Chart review Diabetes mellitus medicine Humans Hypoglycemic Agents Retrospective Studies Glycated Hemoglobin Primary Health Care business.industry Haemoglobin A1c 030503 health policy & services Health Policy Public Health Environmental and Occupational Health medicine.disease Diabetes Mellitus Type 2 Emergency medicine 0305 other medical science business |
| Zdroj: | Journal of Evaluation in Clinical Practice. 27:365-370 |
| ISSN: | 1365-2753 1356-1294 |
| DOI: | 10.1111/jep.13429 |
| Popis: | Clinical inertia, defined as a delay in treatment intensification, is prevalent in people with diabetes. Treatment intensification rates are as low as 37.1% in people with haemoglobin A1c (HbA1c) values7%. Intensification by addition of medication therapy may take 1.6 to more than 7 years. Clinical inertia increases the risk of cardiovascular events. The primary objective was to evaluate rates of clinical inertia in people whose diabetes is managed by both pharmacists and primary care providers (PCPs). Secondary objectives included characterizing types of treatment intensification, HbA1c reduction, and time between treatment intensifications.Retrospective chart review of persons with diabetes managed by pharmacists at an academic, safety-net institution. Eligible subjects were referred to a pharmacist-managed cardiovascular risk reduction clinic while continuing to see their PCP between October 1, 2016 and June 30, 2018. All progress notes were evaluated for treatment intensification, HbA1c value, and type of medication intensification.Three hundred sixty-three eligible patients were identified; baseline HbA1c 9.6% (7.9, 11.6) (median interquartile range [IQR]). One thousand one hundred ninety-two pharmacist and 1739 PCP visits were included in data analysis. Therapy was intensified at 60.5% (n = 721) pharmacist visits and 39.3% (n = 684) PCP visits (P .001). The median (IQR) time between interventions was 49 (28, 92) days for pharmacists and 105 (38, 182) days for PCPs (P .001). Pharmacists more frequently intensified treatment with glucagon-like peptide-1 agonists and sodium glucose cotransporter-2 inhibitors.Pharmacist involvement in diabetes management may reduce the clinical inertia patients may otherwise experience in the primary care setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text